Skip to main content
. 2016 Aug 12;7(36):58181–58192. doi: 10.18632/oncotarget.11276

Figure 4. Lung tumor-derived macrophages release IL-1α after LPS stimulation.

Figure 4

Lung TAMs released higher levels of IL-1α after LPS treatment compared to naïve lung-derived macrophages (A). The inhibition of type I IFN receptor (IFNAR) significantly reduced IL-1α release from lung tumor-derived macrophages after LPS stimulation (B). C3H-derived TAMs released lower levels of IL-1α levels after LPS treatment (C). The addition of LPS to glybenclamide-treated lung TAMs significantly reduced IL-1α levels compared to cells treated with the sole LPS (D). Caspase-1 activity was measured by means FAM-FLICA assay kit and expressed according to the absorbance of FLICA+ cells; lung tumor-derived macrophages shows high levels of FLICA absorbance, confirming the activity of caspase-1 after LPS administration (E). The inhibition of caspase-1 by means Y-Vad (1 μg/mL) significantly reduced the release of IL-1α after LPS addition to lung TAMs (F). Data represent means ± SEM, (n = 12). Statistically significant differences are denoted by *, **and ***indicating p < 0.05, p < 0.01 and p < 0.005, respectively as determined by Student's t test.